000276645 001__ 276645
000276645 005__ 20220930130052.0
000276645 0247_ $$2doi$$a10.4236/wjns.2015.55036
000276645 0247_ $$2ISSN$$a2162-2000
000276645 0247_ $$2ISSN$$a2162-2019
000276645 0247_ $$2Handle$$a2128/9559
000276645 0247_ $$2altmetric$$aaltmetric:4770408
000276645 037__ $$aFZJ-2015-06973
000276645 041__ $$aEnglish
000276645 082__ $$a610
000276645 1001_ $$0P:(DE-Juel1)131839$$aPissarek, Margit$$b0$$eCorresponding author$$ufzj
000276645 245__ $$aPotential PET Ligands for Imaging of Cerebral VPAC and PAC Receptors: Are Non-Peptide Small Molecules Superior to Peptide Compounds?
000276645 260__ $$aIrvine, CA$$bScientific Research Publ.$$c2015
000276645 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1449731381_5832
000276645 3367_ $$2DataCite$$aOutput Types/Journal article
000276645 3367_ $$00$$2EndNote$$aJournal Article
000276645 3367_ $$2BibTeX$$aARTICLE
000276645 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276645 3367_ $$2DRIVER$$aarticle
000276645 520__ $$aPituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) have been known for decades to mediate neuroendocrine and vasodilative actions via G-protein-coupled receptors of Class B. These are targets of imaging probes for positron emission tomography (PET) or single photon emission tomography (SPECT) in tumor diagnostics and tumor grading. However, they play only a subordinate role in the development of tracers for brain imaging. Difficulties in development of non-peptide ligands typical for cerebral receptors of PACAP and VIP are shared by all members of Class B receptor family. Essential landmarks have been confirmed for understanding of structural details of Class B receptor molecular signalling during the last five years. High relevance in the explanation of problems in ligand development for these receptors is admitted to the large N-terminal ectodomain markedly different from Class A receptor binding sites and poorly suitable as orthosteric binding sites for the most small-molecule compounds. The present study is focused on the recently available receptor ligands for PAC1, VPAC1 and VPAC2 receptors as well as potential small-molecule lead structures suitable for use in PET or SPECT. Recently, biaryl, cyanothiophene and pentanamide structures with affinities in nM-range have been proposed as non-peptide ligands at VPAC1 and VPAC2 receptors. However, most of these ligands have been classified as non-competitive related to the orthosteric binding site of endogenous peptide ligands of VPAC receptors. For PAC1 receptors have been identified hydrazide compounds for which an inhibitory and potentially competitive mechanism of receptor binding has been postulated based on molecular docking studies.
000276645 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000276645 588__ $$aDataset connected to CrossRef
000276645 65017 $$0V:(DE-MLZ)GC-130-1$$2V:(DE-HGF)$$aHealth and Life$$x0
000276645 65017 $$0V:(DE-MLZ)GC-150-1$$2V:(DE-HGF)$$aKey Technologies$$x1
000276645 773__ $$0PERI:(DE-600)2681393-2$$a10.4236/wjns.2015.55036$$gVol. 05, no. 05, p. 364 - 384$$n05$$p364 - 384$$tWorld Journal of Neuroscience$$v05$$x2162-2019$$y2015
000276645 8564_ $$uhttps://juser.fz-juelich.de/record/276645/files/WJNS2015.pdf$$yOpenAccess
000276645 8564_ $$uhttps://juser.fz-juelich.de/record/276645/files/WJNS2015.gif?subformat=icon$$xicon$$yOpenAccess
000276645 8564_ $$uhttps://juser.fz-juelich.de/record/276645/files/WJNS2015.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000276645 8564_ $$uhttps://juser.fz-juelich.de/record/276645/files/WJNS2015.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000276645 8564_ $$uhttps://juser.fz-juelich.de/record/276645/files/WJNS2015.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000276645 8564_ $$uhttps://juser.fz-juelich.de/record/276645/files/WJNS2015.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000276645 8767_ $$8scirp-WJNS-1390283-20150902170036$$92015-09-02$$d2015-09-02$$eAPC$$jZahlung erfolgt$$lKK: Heinen$$zUSD 999,-
000276645 909CO $$ooai:juser.fz-juelich.de:276645$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000276645 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000276645 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000276645 9141_ $$y2015
000276645 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131839$$aForschungszentrum Jülich GmbH$$b0$$kFZJ
000276645 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000276645 920__ $$lyes
000276645 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000276645 9801_ $$aUNRESTRICTED
000276645 9801_ $$aFullTexts
000276645 980__ $$ajournal
000276645 980__ $$aVDB
000276645 980__ $$aUNRESTRICTED
000276645 980__ $$aI:(DE-Juel1)INM-5-20090406
000276645 980__ $$aAPC